Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis - Takeaways - MDSpire

Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis

  • By

  • Liwei Sun

  • Jinduo Li

  • Yuan Lv

  • Lin Li

  • Xiaomin Liu

  • September 30, 2025

  • 0 min

Share

  • 1

    Lung cancer, particularly non-small cell lung cancer, is the leading cause of cancer-related deaths globally.

  • 2

    Patients with lung cancer have a high incidence of brain metastases, with poor survival rates for both brain parenchymal and meningeal metastases.

  • 3

    Cerebrospinal fluid is a promising alternative for liquid biopsy to reflect genetic profiles of brain metastases due to low circulating tumor DNA in blood.

  • 4

    The study compares molecular profiles of cerebrospinal fluid in patients with concurrent brain parenchymal and meningeal metastases versus those with meningeal metastases only.

  • 5

    Understanding genomic differences in cerebrospinal fluid can aid in developing targeted therapies and improving treatment strategies for lung cancer patients.

Original Source(s)

Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis

  • by Liwei Sun, Jinduo Li, Yuan Lv, Lin Li, Xiaomin Liu

  • September 30, 2025

Related Content

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases

Outcomes of robotic anatomic lung resection after neoadjuvant therapy for non-small cell lung cancer